• Home
• Responsibility
• CR Report 2004
• Leadership and advocacy
• HIV/AIDS - Accelerating Access Initiative

HIV/AIDS - Accelerating Access Initiative

GSK is a founder member of the Accelerating Access Initiative (AAI) formed in May 2000 as a Public Private Partnership between seven R&D based companies and five UN organisations (UNAIDS, WHO, WB, UNICEF and UNFPA)

The objectives of the AAI are to:

• accelerate sustained access and increase use of appropriate, good quality interventions for the prevention/treatment of HIV/AIDS;
• ensure that care and treatment reach significantly greater numbers of people in need, through new alliances involving committed governments, private industry, the UN, development assistance agencies, non-governmental organisations and people living with HIV/AIDS.

Data released in January 2005 by the AAI estimated that the number of patients in developing countries receiving ARV treatments supplied by the pharmaceutical companies in the AAI reached more than 333,000 by the end of September 2004. This includes 157,500 patients in Africa, a 50% increase since September 2003.

This increase is encouraging but much more needs to be done. The AAI companies are committed to working together to accelerate these trends and bring the benefits of HIV care and treatment to those in need. We will continue to work closely with affected communities, non-governmental organisations, the medical community, governments and multilateral organisations to improve existing initiatives and identify new opportunities.

GSK held the chairmanship of the AAI during 2004 and coordinated a process to review the initiative and ensure that it is as effective as possible in the fight against HIV/AIDS in developing countries.

Back to top